JP2022523066A5 - - Google Patents

Info

Publication number
JP2022523066A5
JP2022523066A5 JP2021543511A JP2021543511A JP2022523066A5 JP 2022523066 A5 JP2022523066 A5 JP 2022523066A5 JP 2021543511 A JP2021543511 A JP 2021543511A JP 2021543511 A JP2021543511 A JP 2021543511A JP 2022523066 A5 JP2022523066 A5 JP 2022523066A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
antibody
cancer
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523066A (ja
JP7549584B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014858 external-priority patent/WO2020154548A2/en
Publication of JP2022523066A publication Critical patent/JP2022523066A/ja
Publication of JP2022523066A5 publication Critical patent/JP2022523066A5/ja
Priority to JP2024147742A priority Critical patent/JP2025000617A/ja
Application granted granted Critical
Publication of JP7549584B2 publication Critical patent/JP7549584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543511A 2019-01-23 2020-01-23 T細胞受容体のデルタ1鎖に特異的な抗体 Active JP7549584B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024147742A JP2025000617A (ja) 2019-01-23 2024-08-29 T細胞受容体のデルタ1鎖に特異的な抗体

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962796061P 2019-01-23 2019-01-23
US62/796,061 2019-01-23
US201962823353P 2019-03-25 2019-03-25
US62/823,353 2019-03-25
US201962847888P 2019-05-14 2019-05-14
US62/847,888 2019-05-14
US201962874313P 2019-07-15 2019-07-15
US62/874,313 2019-07-15
US201962896235P 2019-09-05 2019-09-05
US62/896,235 2019-09-05
US201962931149P 2019-11-05 2019-11-05
US62/931,149 2019-11-05
US201962932156P 2019-11-07 2019-11-07
US62/932,156 2019-11-07
US202062959648P 2020-01-10 2020-01-10
US62/959,648 2020-01-10
PCT/US2020/014858 WO2020154548A2 (en) 2019-01-23 2020-01-23 Antibodies specific to delta 1 chain of t cell receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024147742A Division JP2025000617A (ja) 2019-01-23 2024-08-29 T細胞受容体のデルタ1鎖に特異的な抗体

Publications (3)

Publication Number Publication Date
JP2022523066A JP2022523066A (ja) 2022-04-21
JP2022523066A5 true JP2022523066A5 (https=) 2023-05-30
JP7549584B2 JP7549584B2 (ja) 2024-09-11

Family

ID=71737016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543511A Active JP7549584B2 (ja) 2019-01-23 2020-01-23 T細胞受容体のデルタ1鎖に特異的な抗体
JP2024147742A Pending JP2025000617A (ja) 2019-01-23 2024-08-29 T細胞受容体のデルタ1鎖に特異的な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024147742A Pending JP2025000617A (ja) 2019-01-23 2024-08-29 T細胞受容体のデルタ1鎖に特異的な抗体

Country Status (7)

Country Link
US (2) US12084500B2 (https=)
EP (2) EP4434541A3 (https=)
JP (2) JP7549584B2 (https=)
CN (1) CN114144190B (https=)
AU (1) AU2020212563A1 (https=)
CA (1) CA3127103A1 (https=)
WO (1) WO2020154548A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4269444T3 (pl) * 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
MX2023009544A (es) * 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
WO2025117641A2 (en) * 2023-12-01 2025-06-05 Tavotek Biotherapeutics (Hong Kong) Limited ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US20080248025A1 (en) 2007-03-27 2008-10-09 National Jewish Medical And Research Center Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CN102947335B (zh) * 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
CN102532269B (zh) 2011-05-16 2014-07-09 中国医学科学院基础医学研究所 γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3415534A1 (en) 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
CN107075480A (zh) 2014-07-09 2017-08-18 Tc生物制药有限公司 γδT细胞及其用途
AU2015349878A1 (en) * 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
AU2016274767B2 (en) * 2015-06-09 2022-05-19 Eureka Therapeutics, Inc. T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用

Similar Documents

Publication Publication Date Title
AU2021202413B2 (en) Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
CN106103488B (zh) 靶向TGFβ抑制
US20230227573A1 (en) Anti-cd73 antibodies and compositions
JP2023126946A (ja) 抗lag-3抗体、pd-1経路阻害剤および免疫療法剤の組み合わせを含む組成物
JP2021518103A5 (https=)
JP2018503365A5 (https=)
JP2020103301A5 (https=)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe
JP2021531764A5 (https=)
JP2019529373A5 (ja) 抗Tim−3抗体
JP2019500891A5 (https=)
JP2023523628A5 (https=)
JP2023543152A5 (https=)
EP4273170A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
JP2019500892A5 (https=)
TW201920263A (zh) 檢查點抑制劑雙特異性抗體
KR20180004277A (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
AU2018348429A1 (en) Multispecific antibody
JP2022533418A (ja) 抗ror1/抗cd3二重特異性結合分子
JP7754506B2 (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
JP2022523066A5 (https=)
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
JP2023510429A (ja) 抗ガレクチン-9抗体およびその使用
JP2022513729A5 (https=)
TW202542198A (zh) Cd137結合分子及其用途